Galmed Pharmaceuticals (GLMD) EBITDA Margin (2016 - 2018)
Galmed Pharmaceuticals (GLMD) posted quarterly EBITDA Margin of 81.73% for Q3 2018, down 95636.0% year-over-year from N/an in Q3 2017, and up 87.02% quarter-over-quarter from 43.7% in Q2 2018.
Galmed Pharmaceuticals (GLMD) EBITDA Margin (2016 - 2018) Analysis & Trends
Galmed Pharmaceuticals' EBITDA Margin history runs 3 years deep, the most recent figure standing at 81.73% for Q3 2018.
- In Q3 2018, EBITDA Margin fell 95636.0% year-over-year to 81.73%; the TTM figure through Jun 2019 stood at 261.19% (down 58563.0% YoY), while the FY2018 annual figure was 525.76%, up 61378.0% from the prior year.
- EBITDA Margin for Q3 2018 stood at 81.73%, up from 43.7% in the prior quarter.
- The five-year high for EBITDA Margin was 1971.5% in Q3 2016, with the low at 43.7% in Q2 2018.
- The 3-year median for EBITDA Margin is 1038.1% (2017), against an average of 1049.88%.
- Peak annual rise in EBITDA Margin reached 26306 bps in 2018, while the deepest fall reached 97111 bps in 2018.
- Galmed Pharmaceuticals' EBITDA Margin stood at 1784.31% in 2016, then dropped by 25 bps to 1341.97% in 2017, then tumbled by 94 bps to 81.73% in 2018.
- Business Quant data shows GLMD's EBITDA Margin at 81.73% in Q3 2018, 43.7% in Q2 2018, and 954.85% in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Galmed Pharmaceuticals | 2.39 Mn | -9.49 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 81.73% |
| Jun 30, 2018 | 43.70% |
| Mar 31, 2018 | 954.85% |
| Dec 31, 2017 | 1,341.97% |
| Sep 30, 2017 | 1,038.10% |
| Jun 30, 2017 | 1,014.81% |
| Mar 31, 2017 | 1,217.91% |
| Dec 31, 2016 | 1,784.31% |
| Sep 30, 2016 | 1,971.50% |